- Home
- HCM vs SLNO Comparison
HCM vs SLNO Comparison
Compare HCM & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCM | SLNO |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | Hong Kong | United States |
| Employees | 1811 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | HCM | SLNO |
|---|---|---|
| Price | $15.18 | $52.60 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $13.75 | ★ $90.13 |
| AVG Volume (30 Days) | 32.0K | ★ 5.7M |
| Earning Date | 03-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 108.90 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $1,450,788.00 |
| Revenue This Year | $20.60 | $151.77 |
| Revenue Next Year | $15.62 | $53.58 |
| P/E Ratio | ★ $5.49 | $135.06 |
| Revenue Growth | N/A | ★ 138.82 |
| 52 Week Low | $13.06 | $29.43 |
| 52 Week High | $19.50 | $89.12 |
Technical Indicators
Market Signals| Indicator | HCM | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 59.60 | 77.64 |
| Support Level | $14.69 | $48.91 |
| Resistance Level | $15.49 | $55.47 |
| Average True Range (ATR) | 0.46 | 1.74 |
| MACD | 0.11 | 2.56 |
| Stochastic Oscillator | 73.74 | 99.51 |
Price Performance
Historical ComparisonAbout HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.